ACC2024｜4.6-8 LBCTs试验即将公布！一文速览
2024-03-05 20:11

第73届美国心脏病学会年度科学会议（ACC.24）将于4月6-8日（美国时间）以线上线下结合的形式在美国亚特兰大举行，会议为期3天。

目前官网日程已正式上线，主要日程涉及多板块内容：心电生理学、心力衰竭与心肌病、介入与结构、缺血性心脏病、心脏成像、心脏瓣膜、先天性心脏病、肺血管疾病、血管外科及预防管理等。
严道医声网将会议日程及涉及的重点研究整理公布如下，供各位同道参考学习。

点击 阅读全文 获得完整版日程资讯

本次会议设置了五场最新揭晓的临床试验（Late-Breaking Clinical Trials，LBCTs）专场和三场特色临床研究（Featured Clinical Research，FCR）专场，包含38项最新临床试验研究。


LBCTs相关日程如下：


Session 402｜JACC/ Late-Breaking Clinical Trials I

北京时间：4月6日 21:30-22:22

当地时间：Saturday, April 6; 9:30–10:30 am

线下参会：Main Tent (Hall B1)

1.A Double-blind, Randomized Placebo Procedure-controlled Trial Of An Interatrial Shunt In Patients With HfrEF And HfpEF: Principal Results From The RELIEVE-HF Trial

1.HFrEF合并HFpEF患者采取心房分流术的双盲随机安慰剂对照试验：RELIVE-HF试验的主要结果

2.Empagliflozin After Acute Myocardial Infarction: Results Of The EMPACT-MI Trial

2.恩格列净应用于心肌梗死成人患者临床研究：EMPACT-MI试验结果

3.CSL112 (Apolipoprotein A-I) Infusions And Cardiovascular Outcomes In Patients With Acute Myocardial Infarction (ApoA-I Event Reducing In Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results

3.CSL112（载脂蛋白A-I）输注与急性心肌梗死患者心血管事件结局：载脂蛋白A-I减少缺血性综合征患者事件II）试验主要结果


Late-Breaking Clinical Trials Ⅱ

北京时间：4月7日 21:00-22:15

当地时间：Sunday, April 7; 8:00–9:15 am

线下参会：Main Tent (Hall B1)

4.Effect Of Gamification, Financial Incentives Or Both Combined To Increase Physical Activity Among Patients With Elevated Risk For Major Adverse Cardiovascular Events. The Be Active Randomized Clinical Trial

4.游戏化、经济激励或二者结合对心血管不良事件风险升高患者增加体育活动的影响：BE-ACTIVE随机临床试验

5.Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension - Primary Results From The Phase 2 Kardia-2 Study

5.Zilebesiran联合标准护理对高血压控制不充分患者的降压作用：KARDIA-2 2期研究的主要结果

6.Efficacy And Safety Of Olezarsen In Patients With Hypertriglyceridemia And High Cardiovascular Risk: Primary Results Of The BRIDGE-TIMI 73a Trial

6.Olezaresen治疗高甘油三酯血症合并高心血管风险患者的疗效和安全性：BRIDGE-TIMI 73a试验的主要结果

7.Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

7.Lerodalcibep在极高或高风险心血管疾病患者中稳定降脂治疗的长期疗效和安全性的随机、双盲、安慰剂对照3期研究

8.Plozasiran (ARO-APOC3), An Investigational RNAi Therapeutic, Demonstrates Profound And Durable Reductions In APOC-3 And Triglycerides (TG) In Patients With Severe Hypertriglyceridemia (SHTG), SHASTA-2 Final Results

8.Plozasiran（ARO-APC3）在严重高甘油三酯血症（SHTG）患者中显著持久降低APOC-3和甘油三酯（TG）水平：SHASTA-2最终结果


JACC/ Late-Breaking Clinical Trials III

北京时间：4月7日 22:45-24:00

当地时间：Sunday, April 7; 9:45–11:00 am

线下参会：Main Tent (Hall B1)

9.Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement In Patients With Small Aortic Annuli: Primary Outcomes From The Randomized Smart Trial

9.小主动脉瓣环患者的自膨胀与球囊扩张TAVR对比：随机SMART试验的主要结果

10.Effect Of Edetate Disodium Based Chelation Infusions On Cardiovascular Events In Post-MI Patients With Diabetes: The TACT2 Trial

10.依地酸二钠螯合剂对MI后糖尿病患者心血管事件的影响：TACT2试验结果

11.Long-term Beta-blocker Treatment After Acute Myocardial Infarction And Preserved Left Ventricular Ejection Fraction - The REDUCE-AMI Trial

11.急性心梗后β受体阻滞剂的长期治疗及左心室射血分数的保留：REDUCE-AMI试验结果

12.Percutaneous Transvalvular Micro-axial Flow Pump In Infarct Related Cardiogenic Shock. Results Of The Danger-shock Trial

12.经皮跨瓣微型轴流泵治疗梗死相关心源性休克：DANGER-SHOCK试验结果

13.One-month Ticagrelor Monotherapy After Pci In Acute Coronary Syndromes: Principal Results From The Double-blind, Placebo-controlled Ultimate Dapt Trial
13.急性冠状动脉综合征PCI术后一个月替格瑞洛单药治疗：双盲、安慰剂对照ULTIMATE DAPT试验的主要结果


Late-Breaking Clinical Trials Ⅳ

北京时间：4月8日 21:30-22:45

当地时间：Monday, April 8; 8:30–9:45 am

线下参会：Main Tent (Hall B1)

14.A Selective Aldose Reductase Inhibitor (at-001) For The Treatment Of Diabetic Cardiomyopathy: Primary Results Of The Phase 3 Randomized Controlled Arise-hf Study

14.选择性醛糖还原酶抑制剂AT-001治疗糖尿病性心肌病：3期随机对照ARISE-HF研究的主要结果

15.Efficacy And Safety Of Ninerafaxstat, A Novel Cardiac Mitotrope, In Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results Of IMPROVE-HCM

15.新型心脏促线粒体剂Ninerafaxstat治疗症状性非梗阻性肥厚型心肌病的疗效和安全性：IMPROVE-HCM研究的结果

16.Topical Tranexamic Acid To Reduce Seizures In Cardiac Surgery

16.局部使用氨甲环酸减少心脏手术中的癫痫发作

17.Preventing Cardiac Damage In Patients Treated For Breast Cancer And Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial Of Enalapril To Prevent Anthracycline-induced Cardiotoxicity (PROACT)

17.依那普利应用于接受乳腺癌和淋巴瘤治疗患者的心脏损伤预防：蒽环类心脏毒性的PROACT 3期随机、开放标签、盲终点、优势试验

18.Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial

18.技术辅助非处方瑞舒伐他汀给药后的结果：TACTiC试验研究


Late-Breaking Clinical Trials Ⅴ 

北京时间：4月8日 23:00-4月9日 00:00-01:15

当地时间：Monday, April 8;11:00am.-12:15pm

线下参会：Main Tent (Hall B1)

19.Coronary Sinus Reducer For The Treatment Of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC)

19.冠状窦减径装置治疗难治性心绞痛：ORBITA-COSMIC随机安慰剂对照试验

20.Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement In Patients At Low To Intermediate Risk: One Year Outcomes Of The Randomized DEDICATE-DZHK6 Trial

20.中低风险患者经导管主动脉瓣植入术与外科主动脉瓣置换术的比较：随机DEDICATE-ZHK6试验的一年结果

21.Effect Of Alcohol-mediated Renal Denervation On Blood Pressure In The Presence Of Antihypertensive Drugs: 3-month Primary Results From The Target Bp I Randomized Trial

21.服用降压药患者经酒精介导经皮去肾神经术对血压的影响：TARGET BP I随机试验3个月的主要结果

22.Preventive PCI Or Medical Therapy Alone For Atherosclerotic Coronary Vulnerable Plaques

22.预防性PCI或单独药物治疗动脉粥样硬化性冠状动脉易损斑块

23.Comparison Of Intravascular Ultrasound-guided Versus Angiography-guided Angioplasty For The Outcomes Of Drug-coated Balloon In The Treatment Of Femoropopliteal Artery Disease

23.血管内超声引导与血管造影引导下药物涂层球囊血管成形术治疗股腘动脉疾病的疗效结果对比


下期揭晓FCR专场相关研究，敬请期待！


来源：ACC官网

阅读数: 1489